RAGE-Targeted Nanocomplex for Neurovascular Lesion Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AD treatment strategies focus on single targets such as Aβ and Tau protein, which are poor in clinical efficacy, and lack interventions for targeted repairing of the neurovascular unit, which is crucial for cognitive function, especially in the early stages of AD.
Innovation Solution
A nano complex comprising a lipid, apolipoprotein, and a targeted peptide that covalently links to a nanocarrier to specifically bind to RAGE in cerebrovascular lesions, repairing vascular endothelial cells, promoting Aβ plaque removal, and restoring neurovascular unit components like microglial cells and neurons.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If single target-based drugs (such as γ-secretase inhibitor, 0-secretase inhibitor, or antibody drug mediating Aβ removal) are used to treat AD, then the drug mechanism is simple and easy to develop, but the clinical efficacy is poor and the disease progression cannot be significantly delayed
Solution Approach 1:
The patent combines multiple therapeutic agents into a single nano complex formulation that simultaneously targets multiple pathological features of AD including Aβ plaques, tau tangles, and neurovascular unit damage. This merging approach allows the drug to address multiple disease mechanisms concurrently, thereby improving clinical efficacy while maintaining a single administrable formulation.
Solution Approach 2:
The invention uses a composite nano complex structure containing multiple active components (antibodies, small molecules, or nucleic acids) with different functions. This composite material approach enables the single drug formulation to exert multiple therapeutic effects targeting different pathological aspects of AD, resolving the contradiction between development simplicity and clinical efficacy.
2Measurement precision
If current AD treatment strategies focus on Aβ and Tau protein only, then the treatment target is clear and specific, but the neurovascular unit function is neglected and cognitive impairment cannot be effectively ameliorated
Solution Approach 1:
The nano complex is designed with multi-functionality to simultaneously target multiple pathological features of AD including Aβ plaques, tau tangles, and neurovascular unit components. By incorporating multiple therapeutic agents with different mechanisms of action, the single formulation achieves universal coverage of diverse disease mechanisms while maintaining clear targeting, thereby improving cognitive function outcomes.
Solution Approach 2:
The patent merges targeting of traditional AD markers (Aβ, tau) with targeting of neurovascular unit components into a unified therapeutic approach. This combination allows the treatment to address both the specific molecular targets and the broader neurovascular dysfunction, resolving the contradiction between target specificity and overall therapeutic effectiveness.
3Adaptability or versatility
If conventional drugs are administered systemically, then the drug distribution is broad and covers multiple organs, but the targeted delivery to cerebrovascular lesions is insufficient and cognitive impairment persists
Solution Approach 1:
The nano complex incorporates targeting ligands or antibodies that specifically recognize and bind to markers on neurovascular unit components and pathological features in the brain. This local quality enhancement allows the drug to concentrate its therapeutic effect at the specific site of cerebrovascular lesions while maintaining systemic administration, thereby achieving both broad distribution and precise targeting.
Solution Approach 2:
The patent uses the nano complex structure as an intermediary carrier that facilitates targeted delivery of therapeutic agents to the brain. The nano complex can cross the blood-brain barrier and deliver multiple agents simultaneously to specific brain regions, acting as a mediator between systemic administration and localized therapeutic effect, thus resolving the contradiction between distribution range and targeting accuracy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nano complex effectively targets and repairs neurovascular lesions, improving cerebral blood flow and cognitive impairment by binding to RAGE, enhancing the repair of vascular endothelial cells, microglial cells, and neurons, thereby ameliorating cognitive impairment in AD and diabetic encephalopathy.
Implementation Method 1
the targeted peptide is formed by covalently linking, by means of a bridge structure, a nanocarrier linking end and a peptide chain which targets RAGE
Implementation Method 2
the peptide chain targets RAGE, which specifically binds to a cerebrovascular lesion site
Data Source
AI summary
Nanocomplex for targeted repairing of neurovascular lesion. The nanocomplex comprises a lipid, an apolipoprotein and a targeted peptide, the targeted peptide formed by covalently linking, through a bridge structure, a nanocarrier linking end and a peptide chain targeting RAGE, which specifically binds to cerebrovascular lesion site. Based on AD and the high expression of RAGE in cerebrovascular and brain parenchyma in diabetic encephalopathy, the nanocomplex, as modified by the targeted peptide, can mainly bind, in a targeted manner, to cerebrovascular endothelium by linking the targeted peptide, to repair vascular endothelial cells, promote removal of Aβ plaque near blood vessels, and repair cerebrovascular and neurovascular unit components such as microglial cells, astrocytes and neurons. Ameliorating cognitive impairment is achieved by combined repairing of multiple components and restoring cerebrovascular functions and cerebral blood flow. The nanocomplex has a disease repair effect and can carry drugs, which are delivered to cerebrovascular lesion site.